DRIO vs. CVRX, LUCD, INFU, ICAD, OBIO, MGRM, MBOT, EDAP, GUTS, and NSPR
Should you be buying DarioHealth stock or one of its competitors? The main competitors of DarioHealth include CVRx (CVRX), Lucid Diagnostics (LUCD), InfuSystem (INFU), iCAD (ICAD), Orchestra BioMed (OBIO), Monogram Orthopaedics (MGRM), Microbot Medical (MBOT), Edap Tms (EDAP), Fractyl Health (GUTS), and InspireMD (NSPR). These companies are all part of the "medical equipment" industry.
DarioHealth vs.
DarioHealth (NASDAQ:DRIO) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
DarioHealth has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, CVRx has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
CVRx has a net margin of -116.91% compared to DarioHealth's net margin of -205.62%. DarioHealth's return on equity of -72.16% beat CVRx's return on equity.
DarioHealth has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.
33.4% of DarioHealth shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 10.9% of DarioHealth shares are held by company insiders. Comparatively, 13.9% of CVRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
DarioHealth presently has a consensus target price of $2.00, suggesting a potential upside of 189.81%. CVRx has a consensus target price of $14.50, suggesting a potential upside of 131.63%. Given DarioHealth's higher probable upside, equities research analysts plainly believe DarioHealth is more favorable than CVRx.
DarioHealth received 204 more outperform votes than CVRx when rated by MarketBeat users. However, 73.47% of users gave CVRx an outperform vote while only 67.04% of users gave DarioHealth an outperform vote.
In the previous week, CVRx had 5 more articles in the media than DarioHealth. MarketBeat recorded 11 mentions for CVRx and 6 mentions for DarioHealth. CVRx's average media sentiment score of 1.13 beat DarioHealth's score of -0.30 indicating that CVRx is being referred to more favorably in the news media.
Summary
CVRx beats DarioHealth on 10 of the 18 factors compared between the two stocks.
Get DarioHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DarioHealth Competitors List
Related Companies and Tools
This page (NASDAQ:DRIO) was last updated on 5/22/2025 by MarketBeat.com Staff
